Triptolide sensitizes pancreatic cancer cells to TRAIL-induced activation of the Death Receptor pathway

Academic Article

Abstract

  • The tumor necrosis factor related apoptosis-inducing ligand (TRAIL) causes cancer cell death, but many cancers, including pancreatic cancer, are resistant to TRAIL therapy. A combination of TRAIL and the diterpene triepoxide, triptolide, is effective in inducing pancreatic cancer cell death. Triptolide increases levels of death receptor DR5 and decreases the pro-survival FLICE-like inhibitory protein (c-FLIP), which contribute to the activation of caspase-8. This combination further causes both lysosomal and mitochondrial membrane permeabilization, resulting in cell death. Our study provides a mechanism by which triptolide sensitizes TRAIL resistant cells, which may become a novel therapeutic strategy against pancreatic cancer. © 2014 Elsevier Ireland Ltd.
  • Published In

  • Cancer Letters  Journal
  • Digital Object Identifier (doi)

    Author List

  • Chen Z; Sangwan V; Banerjee S; Chugh R; Dudeja V; Vickers SM; Saluja AK
  • Start Page

  • 156
  • End Page

  • 166
  • Volume

  • 348
  • Issue

  • 1-2